NCT05970705View on ClinicalTrials.gov

Regorafenib Combined With TAS-102 Versus Regorafenib Monotherapy in Third or Later Line Therapy of mCRC

PHASE2RecruitingINTERVENTIONAL
Enrollment

101

Participants

Timeline

Start Date

July 1, 2023

Primary Completion Date

July 4, 2025

Study Completion Date

July 4, 2026

Conditions
Metastatic Colorectal Cancer
Interventions
DRUG

Regorafenib

this anti-angiogenesis targeting drug is one of the standard third-line treatment options for patients with metastatic colorectal cancer

DRUG

Trifluridine/Tipiracil

this chemotherapeutic drug is also one of the standard third-line treatment options for patients with metastatic colorectal cancer

Trial Locations (1)

200032

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER